RNA-based therapy can protect from many Covid variants: Study


PTI, Jan 4, 2022, 12:49 PM IST

An RNA molecule that stimulates the body’s early antiviral defence system may provide protection against a range of SARS-CoV-2 variants, including Delta, according to a study conducted in mice.

Ribonucleic acid (RNA) is a single stranded molecule essential in various biological roles and expression of genes.

Researchers at Yale School of Medicine in the US noted that the molecule could lead to new treatments for COVID-19 in immunocompromised patients. The research, published recently in the Journal of Experimental Medicine (JEM), could also provide an inexpensive therapeutic option for many developing countries that currently lack access to vaccines.

The study was conducted before Omicron was identified and did not test for the variant which is behind the current spike in COVID-19 cases in many countries.

The researchers noted that the vaccines against SARS-CoV-2 are highly effective at preventing severe disease and death.

However, vaccine availability is extremely limited in many low-income countries, and vaccine-resistant strains of the virus are also emerging, they said.

”This is why, in addition to the use of vaccines in preventing COVID-19, efforts are required to develop efficacious therapeutics against SARS-CoV-2,” said Akiko Iwasaki, a professor at Yale School of Medicine.

The body’s first line of defence against SARS-CoV-2 — before the involvement of antibodies and T cells — is thought to depend on receptor molecules such as RIG-I.

These molecules recognise the virus’s genetic material and induce the production of signalling proteins known as type I interferons.

These interferons promote the production of proteins that can inhibit viral reproduction and stimulate the recruitment of immune cells to fight the infection, the researchers said.

Multiple studies have suggested that early and robust production of interferons protects against COVID-19, whereas delayed production is associated with severe disease.

A clinical trial has shown that treating COVID-19 patients with purified interferon protein early during disease can reduce mortality, but manufacturing interferons is extremely expensive.

The latest study suggests a cheaper option in the form of short RNA molecules that mimic SARS-CoV-2’s genetic material and activate the RIG-I receptor to stimulate production of type I interferons by the body’s own cells.

The researchers tested their approach in mice susceptible to SARS-CoV-2 infection. A single dose of an RNA molecule named SLR14 was sufficient to protect the mice from severe disease and death, particularly if the treatment was provided shortly before or soon after exposure to the virus, the researchers said.

When administered shortly after viral infection, SLR14 was more effective than treating mice with purified interferon protein, they said. SLR14 protected mice from all emerging SARS-CoV-2 variants, including Delta.

The researchers tested SLR14 in immunocompromised mice chronically infected with SARS-CoV-2. The RNA molecule was able to completely clear the virus from these animals, even though they lack both T cells and antibody-producing B cells.

The researchers noted that RNA molecules like SLR14 are relatively cheap and easy to manufacture.

”SLR14 therefore holds great promise as a new class of RNA therapeutics that can be applied as antivirals against SARS-CoV-2,” Iwasaki added.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

‘COVID was different’: SC bemoans distribution of free ration

Nagarjuna’s younger son Akhil Akkineni engaged

People getting heartburns after I became CM for second time: Siddaramaiah

Newborn baby kidnapped from Kalaburagi hospital in Karnataka

Gukesh draws with Liren in second game of World Chess Championship

All about ‘One Nation One Subscription’ scheme

PAN cards with QR code planned under PAN 2.0 project

Related Articles More

Will impose 25 per cent tariff on all imports from Canada, Mexico: Trump

Internal divisions leave open question whether Gandhi’s vision will ever be fully realised in India: Bill Clinton

COP29: India rejects new USD 300 billion climate finance deal

Royal tour of India in offing for King Charles, Queen Camilla: Report

Indian-American leaders applaud PM Modi for inclusive growth in India

MUST WATCH

Grafting

Coconut Flower

Prakash Belawadi

Naxal Leader Vikram Gowda

Christmas Cake Fruit Mixing


Latest Additions

‘COVID was different’: SC bemoans distribution of free ration

Telugu actor Shri Tej booked for alleged cheating, false marriage promise

Five arrested in connection with botched angioplasty deaths at Gujarat hospital

Deceased Kannur official’s widow moves Kerala HC for CBI probe into his death

CAMPCO urges Centre to take action on areca nut ‘carcinogen classification’

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.